Amicus reports Q4 non-GAAP EPS 9c, consensus 9c

Reports Q4 net product revenue $149.7M, consensus $147.87M. “We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver continued revenue growth and accelerating profitability in 2025 and the years ahead. We have firmly established Amicus (FOLD) as a unique biotechnology company: two growing medicines with long runways, a leverageable infrastructure with patients at the center, and the financial strength to continue to build the business and our leadership in rare diseases,” said Bradley Campbell, President and CEO.